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The clinical outcome of gastric cancer has gradually improved, but the prognosis of patients at the advanced stage is still poor. Thus, better understanding of the biology and development of molecular test for early detection of gastric cancer are crucial in this respect.
Many solid tumors, including gastric cancer, show defects in the maintenance of genomic stability, frequently resulting in DNA copy number alterations. (3, 4) Comparative genomic hybridization (CGH) with total genomic DNA from test and reference cell population was the first efficient approach to scanning the entire genome for variations in DNA copy number. However, because of the difficulty in obtaining sufficient metaphase chromosome spreads for classical banding analyses from primary cancer tissues, there is little information on cytogenetic change of gastric cancer. ArrayCGH with elements produced by spotting DNA made from genomic clones, cDNAs, selected polymerase chain reaction (PCR) products, and oligonucleotides is a more powerful tool for the rapid and ac-curate detection of specific gene copy number change, allowing the identification of novel candidate genes in tumorigenesis. To date, a number of reports have described the CGH analysis of gastric cancers.(4-6) Interestingly, it has been reported that gastric cancer is a heterogenous disease at the genomic level and that different patterns of DNA copy number aberrations are correlated to differences in clinical behavior and patient outcome. (5, 6) For example, the degree of genetic change at the DNA ploidy level correlated well with tumor stage in diffuse-type gastric cancers, while such a correlation was poor in intestinal-type gastric cancer. (7, 8) The present study aimed to unravel DNA copy number alterations in gastric cancers and to identify novel candidate genes that may contribute to the development or progression of gastric cancer.
Therefore, we applied arrayCGH analysis to 23 gastric adenocarcinomas and found the UQCRFS1 candidate gene with high-level gains (amplification) and overexpression in gastric cancers.
Materials and Methods

Samples
Methacarn fixed paraffin-embedded, twenty three advanced gastric cancer specimens were enrolled in this study. Of them, 14 cases were of the intestinal-type, 5 were of the diffuse-type and 4 were of the mixed-type. Approval was obtained from the institutional review board of The Catholic University of Korea, College of Medicine (CUMC09U043). There was no evidence of familial cancer in any of the patients.
Microdissection and DNA extraction
The tumor cells were selectively procured from Hematoxylin & Eosin stained slides using a laser microdissection device (ION LMD, JungWoo International Co, Seoul, Korea). The surrounding non-cancerous gastric mucosal cells were also obtained to study the corresponding normal DNA from the same slides in all cases.
DNA extraction was performed using commercially available DNA isolation kits (AIAamp DNA mini kit; Qiagen, Hilden, Germany).
Array-comparative genome hybridization (array CGH) analysis
We used oligo arrayCGH microarrays (Agilent Technologies, Palo Alto, CA, USA), which contained over 43,000 probes representing coding and noncoding human sequences. Genomic DNAs extracted from the gastric cancers and corresponding gastric mucosae were labeled with Cy5 and Cy3, respectively, and competitively hybridized on the microarrays for 24 hours. After washing microarrays, the microarrays were scanned using GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA) and Feature Extraction Software (Agilent Technologies) was used to calculate signal intensities of fluorescent dyes on each probes. Copy number alterations spanning less than three probes were excluded to increase specificity.
Quantitative real-time PCR method
Primers were designed using the Primer3. 
Immunohistochemistry for UQCRFS1
One hundred eighty six formalin-fixed paraffin-embedded gastric cancer specimens were examined for UQCRFS1 im- 
Statistical analysis
The Chi-square test for association was used to examine the relationship between UQCRFS1 expression and the clinicopathological parameters of gastric cancers. A P-value less than 0.05 was considered to be of statistical significance.
Results
ArrayCGH analysis and amplification of UQCRFS1
ArrayCGH was successfully performed in 23 gastric cancer cases. To identify tumor-specific genomic alterations, we normalized the gastric cancer profiles against the matched gastric mucosae and copy number changes, which were found in less than three cases, were excluded. Loci with amplification were defined as a mean test/reference ratio above 1.5 and loci with a test/reference ratio below 0.5 were considered as losses. (Fig. 1) . Furthermore, amplification of the UQCRFS1 was confirmed by quantitative realtime PCR and increased copy number of UQCRFS1 was detected in 5 (20%) of 25 gastric cancer DNAs (Fig. 2) .
Immunohistochemistry of UQCRFS1 expression
A weak to moderate immunopositivity for UQCRFS1 was clearly marked on the cytoplasm and nucleus of corresponding gastric mucosal epithelial cells and some lymphocytes (Fig. 3) .
However, the surrounding stromal cells such as fibroblasts were negative for UQCRFS1. Overexpression of the UQCRFS1 protein was detected in 105 (56.5%) of the 186 gastric cancers. Interestingly, dysplastic cells in surrounding gastric mucosa also showed strong Fig. 2 . Copy number change of UQCRFS1 in gastric cancers. In real time polymerase chain reaction, copy number ratio was calculated based on the corresponding normal value of each case. UQCRFS1 copy number was increased more than 1.5 fold in 5 (20%) of 25 gastric cancer DNAs compared to the surrounding gastric mucosal tissue DNAs. Cont = control; T = tumor.
Fig. 3.
Immunostaining of the UQCRFS1 protein in gastric cancer. Expression of the UQCRFS1 protein in gastric cancers. Low-power view (×2, magnification) of tissue cores stained for UQCRFS1. Immunostaining for UQCRFS1 was detected in cytoplasm and nucleus of non-cancerous gastric mucosal epithelial cells (×200, magnification) (A, B). Overexpression of UQCRFS1 protein was seen in well differentiated adenocarcinoma (C) and moderate differentiated adenocarcinoma (D) (×200, magnification).
UQCRFS1 expression (Fig. 3) 
UQCRFS1 expression in gastric cancer cell lines and tissues
The expression of the UQCRFS1 protein was also examined by immunoblotting using total proteins extracted from gastric cancer cell lines and tissues with anti-UQCRFS1 antibody (Fig. 4) .
Overexpression of the UQCRFS1 was found in 6 (66.7%) of 9 gastric cancer cell lines and 12 (50%) of 24 cancer tissues. Actin and GAPDH levels, as controls for loading, were consistent in these cell lines and tissues.
Discussion
DNA copy number aberrations are hallmarks of various human cancers. In this study, we investigated DNA copy number changes in 23 gastric cancers by arrayCGH and found frequent chromosomal losses and gains in gastric carcinomas (Table 2, Since the copy number ratio of test to normal DNA was more than 2 fold at this locus, we considered the UQCRFS1 gene as novel target gene for gastric cancer development or progression. In quantitative real-time PCR, increased copy number of the UQCRFS1 gene (Table 1 ). In addition, we confirmed overexpression of the UQCRFS1 protein in human gastric cancer cell lines and tissues by Western blot (Fig. 4) . According to the re- In addition, we also confirmed overexpression UQCRFS1 protein in 6 (66.7%) of 9 gastric cancer cell lines and 12 (50%) of 24 gastric cancer tissues by immunoblotting. All of these results suggest that overexpression of the UQCRFS1 gene may contribute to the development or progression of gastric cancers.
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